Peptide profile
Published Data as of
In two randomized trials in people, bremelanotide raised desire scores and lowered distress about low desire more than placebo.1 The trials in people enrolled premenopausal women with hypoactive sexual desire disorder (HSDD).1 The FDA approved bremelanotide as Vyleesi in 2019 for premenopausal women with acquired, generalized HSDD.2 Nausea, flushing and headache were more frequent than with placebo in both trials in people.1
The FDA approved Bremelanotide (PT-141) in 2019 under the name Vyleesi.2 The FDA indication is for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that causes marked distress or interpersonal difficulty.2 The FDA lists it as not indicated for postmenopausal women, men, or to enhance sexual performance.2
As of November 15, 2026, PepBank holds 100 findings in people for bremelanotide from 20 publications.5 In the evidence class of animal studies, PepBank holds 18 findings in animals from 6 publications.5 Among the peptides in PepBank, bremelanotide has 10 registered trials in the trial registry records.5
PepBank lists 28 Bremelanotide (PT-141) studies with results where the peptide was the one given.5 Those studies hold 128 results in PepBank's records.5
In two randomized trials in people with HSDD, bremelanotide raised Female Sexual Function Index (FSFI) desire scores more than placebo.1 The differences in these trials in people were 0.3 and 0.42 points, and 0.35 points in the integrated analysis.1 Distress about low desire changed more than with placebo in people, by -0.37 and -0.29 points, and -0.33 points integrated.1
In a trial in people with HSDD, bremelanotide improved Elements of Desire Questionnaire scores more than placebo after 6 months.6 This held in people for both the monthly and the daily recall versions.6
In a dose-finding trial in people with female sexual dysfunctions, pooled bremelanotide raised satisfying sexual events by 0.7 per month, against 0.2 with placebo.7 In that trial in people, the FSFI total score rose 3.6 points, against 1.9 with placebo.7 The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score changed by -11.1 points in that trial in people, against -6.8 with placebo.7
Researchers ran subgroup analyses of the RECONNECT trials in people with HSDD.3 In those trials in people, bremelanotide improved desire versus placebo across age, weight, BMI and bioavailable testosterone subgroups, with few exceptions.3 It also reduced distress about low desire in people across the same subgroups, with few exceptions.3
In both trials in people with HSDD, nausea, flushing and headache were more frequent with bremelanotide than with placebo.1 Each occurred at 10% or more in both studies in people.1 Most treatment-emergent adverse events in people were about tolerability and were mild or moderate.1
| Side effect | Bremelanotide | Placebo |
|---|---|---|
| Nausea, in trials in people | 40% in people on bremelanotide | 1.3% in people on placebo4 |
| Flushing, in trials in people | 20.3% in people on bremelanotide | 1.3% in people on placebo4 |
| Headache, in trials in people | 11.3% in people on bremelanotide | 1.9% in people on placebo4 |
| Injection site reactions, in trials in people | 5.4 in people on bremelanotide | 0.5 in people on placebo4 |
The two randomized controlled trials in people with HSDD used a studied amount of 1.75 mg, given subcutaneously.1 The subgroup analyses in people looked at the same studied 1.75 mg subcutaneous amount from randomized controlled trials.3 A randomized controlled trial of blood pressure in people compared studied subcutaneous amounts of 1.25 mg and 1.75 mg.8
| Kind | Dose | Species | Route | Design | Source |
|---|---|---|---|---|---|
| Studied dose | 1.75 mg | people | subcutaneous | randomized controlled trial | [1] |
| Studied dose | 1.75 mg | people | subcutaneous | randomized controlled trial | [3] |
| Studied dose | 1.25 mg | people | subcutaneous | randomized controlled trial | [8] |
| Studied dose | 1.75 mg | people | subcutaneous | randomized controlled trial | [8] |
PepBank records the peptide as Bremelanotide (PT-141), with 28 studies with results.5 The FDA approved bremelanotide under the name Vyleesi in 2019.2 The FDA indication is for premenopausal women with acquired, generalized HSDD that causes marked distress or interpersonal difficulty.2 The FDA lists it as not indicated for postmenopausal women, men, or to enhance sexual performance.2
In a randomized trial in people with female sexual dysfunction, bremelanotide raised ambulatory systolic blood pressure versus placebo in the first hours after each dose.8 With the lower studied amount in people, the rises were 2.4 and 3 mmHg.8 With the higher one in people, they were 3.1 and 3.2 mmHg, and heart rate fell.8 Diastolic pressure rose in a similar way in people.8
In a randomized trial in healthy adults, single intranasal bremelanotide doses with or without ethanol were safe and generally well tolerated.9 In that trial in people, no clinically significant pharmacokinetic interaction with ethanol was found, overall or by sex.9 No participants in this trial in people stopped because of adverse events.9 No drug-related serious adverse events were reported in people.9
In a randomized trial in men with erectile dysfunction, intranasal PT-141 plus sildenafil gave a greater erectile response than sildenafil alone.10 The combination was well tolerated in people, with no new adverse events.10 It also showed no increase in frequency or severity of adverse events in people compared with monotherapy.10 The FDA lists Vyleesi as not indicated for men.2
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated